An explicative review of the pharmacological activities of 1,2,3-Triazole linked Benzimidazole derivatives.

Abstract

Benzimidazole and 1,2,3-triazole are two significant heterocyclic scaffolds widely explored in medicinal chemistry due to their diverse pharmacological properties. These structural motifs exhibit remarkable antimicrobial and antiviral activities, making them attractive candidates for drug design and development. Benzimidazole derivatives are known for their ability to target bacterial and fungal pathogens, while 1,2,3-triazole-linked compounds have demonstrated potent antiviral efficacy against a range of viruses, including influenza and coronaviruses. The combination of these pharmacophores in hybrid molecules has led to the development of novel therapeutic agents with enhanced bioactivity and selectivity. This review highlights the synergistic effects of combining these two pharmacophores in drug design, emphasizing their enhanced efficacy against a range of microbial and viral pathogens. The paper discusses the structural-activity relationship (SAR) of these hybrid molecules, their mechanisms of action, and their potential as novel therapeutic agents. The exploration of these conjugated systems offers promising insights into the future of antimicrobial and antiviral drug discovery, addressing the urgent need for novel treatments in an era of rising resistance and emerging viral threats. The review underscores the growing interest in these hybrid molecules as promising candidates for addressing the rising challenge of drug-resistant infections and emerging viral diseases, providing valuable insights for future drug discovery and development.